Local effects of malignancy on bone

Sue A. Brown, Gregory A. Clines, Theresa A. Guise

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

PURPOSE OF REVIEW: Skeletal-related complications occur commonly in many solid tumors including breast, prostate and lung cancer as well as multiple myeloma. In addition, malignancies and their associated treatment may result in bone loss or osteoporosis. This review will focus solely on recent data associated with metastatic bone disease with a focus on breast cancer, prostate cancer and multiple myeloma. Bone loss or osteoporosis associated with cancer will be covered in a separate article in this issue. RECENT FINDINGS: Recent progress in understanding the pathophysiology of bone metastases has pointed to several novel pathways: transforming growth factor β; receptor activator of nuclear factor β ligand and osteoprotegerin; and Wnt signaling pathways and associated factors such as dickkopf-1 and endothelin-1. SUMMARY: The identification of new pathways is important in metastatic bone disease from cancer and has allowed for the development of novel therapeutics aimed at preventing the devastating complications of bone metastases. Bisphosphonates remain the predominant therapy in use for the treatment and prevention of skeletal-related adverse effects from cancer.

Original languageEnglish (US)
Pages (from-to)436-441
Number of pages6
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2007

    Fingerprint

Keywords

  • Bisphosphonates
  • Bone
  • Cancer
  • Metastases

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this